GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (LSE:AVO) » Definitions » Retained Earnings

Advanced Oncotherapy (LSE:AVO) Retained Earnings : £-167.22 Mil (As of Jun. 2022)


View and export this data going back to 2006. Start your Free Trial

What is Advanced Oncotherapy Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Advanced Oncotherapy's retained earnings for the quarter that ended in Jun. 2022 was £-167.22 Mil.

Advanced Oncotherapy's quarterly retained earnings declined from Jun. 2021 (£-135.01 Mil) to Dec. 2021 (£-151.50 Mil) and declined from Dec. 2021 (£-151.50 Mil) to Jun. 2022 (£-167.22 Mil).

Advanced Oncotherapy's annual retained earnings declined from Dec. 2019 (£-98.50 Mil) to Dec. 2020 (£-122.27 Mil) and declined from Dec. 2020 (£-122.27 Mil) to Dec. 2021 (£-151.50 Mil).


Advanced Oncotherapy Retained Earnings Historical Data

The historical data trend for Advanced Oncotherapy's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Retained Earnings Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -57.72 -78.81 -98.50 -122.27 -151.50

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -109.15 -122.27 -135.01 -151.50 -167.22

Advanced Oncotherapy Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Advanced Oncotherapy  (LSE:AVO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Advanced Oncotherapy (LSE:AVO) Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.